Allogeneic Stem Cell Transplant Overview

 

High-dose chemotherapy and allogeneic bone marrow or blood stem cell transplantation is a treatment strategy that uses the administration of high doses of anticancer drugs and/or radiation therapy for the purpose of killing cancer cells and transplantation of stem cells to "rescue" or restore bone marrow blood and immune cell production. Transplantation is the term for transfer of tissue (a graft) from one person to another. Allogeneic is the term for a tissue graft from one person to another.

There are many types of allogeneic grafts that can be transplanted from one person to another, including skin, heart, kidney, liver, etc. However, the easiest organ in the body to transplant is the bone marrow. This is because a small quantity of stem cells taken from the bone marrow or peripheral blood of one person can repopulate the entire bone marrow organ of another person. In contrast to other types of transplants, the donor does not "miss" the small amount of bone marrow stem cells removed. A small quantity of bone marrow contains stem cells that are capable of dividing rapidly and repopulating the entire blood and immune system of another person within a short period of time.

High-dose chemotherapy and allogeneic stem cell transplantation is a component of an overall treatment strategy used to treat many kinds of cancer. High-dose chemotherapy and allogeneic stem cell transplantation may be appropriately used as the initial or subsequent treatment, depending on the type of cancer. It is not a treatment of last resort. The role of stem cell transplantation in the management of a specific cancer should be carefully planned following an initial diagnosis of cancer. To learn more about allogeneic stem cell transplantation and the role it may play in the treatment of your cancer, select one of the following.

This content was last modified on May 23, 2006 .
Latest Cancer News
Vaccine Against HPV-16 Effective for Vulvar Intraepithelial Neoplasia

November 6, 2009 — Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.

Small HER2-positive Breast Cancers Have a Higher Risk of Recurrence

November 6, 2009 — Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.

Alcohol May Reduce Risk of Thyroid Cancer

November 6, 2009 — Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.

Select news items provided by Reuters Health